New hope for aggressive lung cancer: experimental drug combo enters human testing
NCT ID NCT06077500
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 23 times
Summary
This early-phase study tests a new experimental drug called BI 764532 (obrixtamig) combined with standard chemotherapy and immunotherapy for adults with extensive-stage small cell lung cancer. The main goal is to find the highest safe dose of BI 764532 when given with standard treatments. Participants receive all treatments as infusions and are closely monitored for side effects and response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CARCINOMA (SCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AZ Groeninge
Kortrijk, 8500, Belgium
-
Cliniques Universitaires Saint-Luc
Brussels, 1200, Belgium
-
Emory University
Atlanta, Georgia, 30322, United States
-
Fundación Jiménez Díaz
Madrid, 28040, Spain
-
HOP Civil
Strasbourg, 67091, France
-
Hamamatsu University Hospital
Shizuoka, Hamamatsu, 431-3192, Japan
-
Hospital Universitario Ramon Y Cajal
Madrid, 28034, Spain
-
Hospital Universitario Virgen De La Macarena
Seville, 41009, Spain
-
Hôpital Louis Pradel
Bron, 69677, France
-
INS Bergonie
Bordeaux, 33000, France
-
Institut Gustave Roussy
Villejuif, 94805, France
-
Instituto Valenciano de Oncología
Valencia, 46009, Spain
-
Japanese Foundation for Cancer Research
Tokyo, Koto-ku, 135-8550, Japan
-
MED POLONIA SP Z O O, Clinical Trials Department,Poznan
Poznan, 60-693, Poland
-
Medical University Gdansk
Gdansk, 80-214, Poland
-
National Cancer Center Hospital
Tokyo, Chuo-ku, 104-0045, Japan
-
Orlando Health Cancer Institute
Orlando, Florida, 32806, United States
-
Polish Mother's Memorial Hospital - Research Institute
Lodz, 93-338, Poland
-
Saitama Medical University International Medical Center
Saitama, Hidaka, 350-1298, Japan
-
University Hospital of Lausanne
Lausanne, 1011, Switzerland
-
Universitätsklinikum Gießen und Marburg GmbH
Giessen, 35392, Germany
Conditions
Explore the condition pages connected to this study.